Drug-induced reversion of progression phenotype is accompanied by reversion of AP-1 phenotype in JB6 cells

In Vitro Cellular and Developmental Biology - Animal

Volumn 32, Issue 4, 1996, Pages 234-237

  Lavrovsky, V ^a,b   Dong, Z ^a,c   Ma, W Y ^c   Colburn, N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

AP 1 activity; revertant cells; transformed cells

Indexed keywords

BETA GALACTOSIDASE; CYCLIC AMP; EPIDERMAL GROWTH FACTOR; FLUOCINOLONE ACETONIDE; FORSKOLIN; GLUCOCORTICOID; LUCIFERASE; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSCRIPTION FACTOR AP 1;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; EPIDERMIS CELL; GENETIC TRANSFECTION; MOUSE; NONHUMAN; PHENOTYPE; REVERTANT;

ANIMALIA;

EID: 0029943993     PISSN: 10712690     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02722951     Document Type: Article

References (15)

1. Bernstein, L. R.; Colburn, N. H. AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science 244: 566-569; 1989.
2. Colburn, N. H.; Former, B. F.; Nelson, K. A., et al. Tumor promoter induces anchorage independence irreversibly. Nature (Lond.) 281: 589-591; 1979.
3. Colburn, N. H.; Gindhart, T. Specific binding of transforming growth factor correlates with promotion of anchorage independence in EGF receptorless JB6 cells. Biochem. Biophys. Res. Commun. 102:799-807; 1981.
4. Colburn, N. H.; Vorder Bruegge, W. F.; Bates, J. R., et al. Correlation of anchorage independent growth with tumorigenicity of chemically transformed mouse epidermal cells. Cancer Res. 38:624-634; 1978.
5. Dong, Z.; Birrer, M. J.; Watts, R. G., et al. Blocking tumor promoter induced AP-1 activity inhibits induced transformation in JB6 cells. Proc. Natl. Acad. Sci. USA 91:609-613; 1993.
6. Dong, Z.; Lavrovsky, V. A.; Colburn, N. H. Induction of reverse transformation in JB6 RT101 cells by AP-1 inhibitors. Carcinogenesis 16:749-756; 1995.
7. Kitayama, H.; Sugimoto, Y.; Matsuzaki, T., et al. A ras-related gene with transformation suppressor activity. Cell 56:77-84; 1989.
8. Kolch, W.; Heidecker, C.; Troppmair, J., et al. Raf revertant cells resist transformation by non-nuclear oncogenes and are deficient in the induction of response genes by TPA and serum. Oncogene 8:361-370; 1993.
9. Krzyzosiak, W. J.; Shindo-Okada, N.; Teshima, H., et al. Isolation of genes specifically expressed in flat revertant cells derived from activated ras-transformed NIH 3T3 cells by treatment with azatyrosine. Proc. Natl. Acad. Sci. USA 89:4879-4883; 1992.
10. Lavrovsky, V. A.; Guvakova, M. A.; Lavrovsky, J. V. High frequency of tumor cell reversion to non-tumorigenic phenotype. Eur. J. Cancer 28:17-21; 1992.
11. Lea, M. A. Action of exogenous differentiating agents on genes expression in cancer cells. Crit. Rev. Oncol. Hematol. 13:189-214; 1992.
12. Noda, M. Mechanisms of reversion. FASEB J. 7:834-840; 1993.
13. Takahashi, K.; Heine. U. I.; Junker, J. L., et al. Role of cytoskeleton changes and expression of the H-ras oncogene during promotion of neoplastic transformation in mouse epidermal JB6 cells. Cancer Res. 46:5923-5932; 1986.
14. Tanaka, K.; Yanoshita, R.; Konishi, M., et al. Suppression of tumorigenicity in human colon carcinoma cells by introduction of normal chromosome 1p36 region. Oncogene 8:2253-2258; 1993.
15. Wisdom, R.; Verma. I. M. Revertants of V-fos-transformed rat fibroblasts: suppression of transformation is dominant. Mol. Cell. Biol 10:5626-5633; 1990.